First Spanish programme selected

03 May 2016

The first drug target programme from Spain has been selected by The European Lead Factory. It involves an epigenetic target against cancer that is being investigated by the Center for Applied Medical Research (CIMA) at the University of Navarra.

Dr. Julen Oyarzabal, Director of Translational Science and the Molecular Therapy Program at CIMA, explains, “The goal of this project is to identify new molecules that enable more effective treatments against cancer with fewer side effects”. At the same time, he says, “our study also allows us to assess their impact on other diseases of the central nervous system, cardiac complaints and metabolic illnesses”. 

The picture shows the laboratory researchers involved in discovering small molecules at CIMA, from left to right: Julen Oyarzabal, Irene de Miguel Turullols, Elena Saez de Blas, Juan Antonio Sánchez and Obdulia Rabal.